_
Rehovot's SciGen Announces Marketing Approval of Hepaptitis Vaccine in India
SciGen announces the marketing approval of its third generation hepatitis B vaccine, Sci-B-Vac. in India. Commercialization of the vaccine will commence as soon as the manufacturing facility in Rehovot, Israel is commissioned. Commissioning is expected in the second quarter of 2007.
SciGen Limited (ASX: SIE) announces the marketing approval of its third generation hepatitis B vaccine, Sci-B-Vacin India. Commercialization of the vaccine will commence as soon as the manufacturing facility in Rehovot, Israel is commissioned. Commissioning is expected in the second quarter of 2007.
India forms the second largest pool of Hepatitis B carriers in the world. It is estimated that at least 45 Million people in India were infected with Hepatitis B in 2005, 10% develop chronic infection and 89000 people were estimated to have died of Hepatitis. Revenues in 2005 were estimated to be over US$40 Million dollars with a compounded growth rate of 6% (1). SciGen hepatitis B vaccine will be distributed by Shreya Life Sciences, one of the top 20 pharmaceutical companies in India.
About Sci-B-Vac:
Sci-B-Vacis a third generation recombinant vaccine produced in mammalian cells culture (CHO) that contains all three regions (epitope) of the hepatitis B virus surface antigen (proteins) and elicit a faster immune response than other hepatitis B vaccine presently available. Sci-B-Vac has been proven safe and effective after testing in more than 5000 men, women, children and newborn in the Asia Pacific Region, Europe and Israel.
About SciGen:
SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market. SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherland
Source: SciGen Ltd., pipelinereview.com (8 Nov 2006) [FullText]
SciGen Limited (ASX: SIE) announces the marketing approval of its third generation hepatitis B vaccine, Sci-B-Vacin India. Commercialization of the vaccine will commence as soon as the manufacturing facility in Rehovot, Israel is commissioned. Commissioning is expected in the second quarter of 2007.
India forms the second largest pool of Hepatitis B carriers in the world. It is estimated that at least 45 Million people in India were infected with Hepatitis B in 2005, 10% develop chronic infection and 89000 people were estimated to have died of Hepatitis. Revenues in 2005 were estimated to be over US$40 Million dollars with a compounded growth rate of 6% (1). SciGen hepatitis B vaccine will be distributed by Shreya Life Sciences, one of the top 20 pharmaceutical companies in India.
About Sci-B-Vac:
Sci-B-Vacis a third generation recombinant vaccine produced in mammalian cells culture (CHO) that contains all three regions (epitope) of the hepatitis B virus surface antigen (proteins) and elicit a faster immune response than other hepatitis B vaccine presently available. Sci-B-Vac has been proven safe and effective after testing in more than 5000 men, women, children and newborn in the Asia Pacific Region, Europe and Israel.
About SciGen:
SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market. SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherland
Source: SciGen Ltd., pipelinereview.com (8 Nov 2006) [FullText]
0 Comments:
Post a Comment
<< Home